Vericel to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021

Rhea-AI Summary

Vericel Corporation (NASDAQ:VCEL) announced that CEO Nick Colangelo will present a company overview at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 4:40 p.m. Eastern Time. The event will be conducted virtually, allowing investors to access a live webcast via the Investor Relations section of Vericel's website. Vericel specializes in advanced therapies for sports medicine and severe burn care, offering MACI and Epicel as leading cell therapy products.

CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the Goldman Sachs 42^nd Annual Global Healthcare Conference. The conference is being conducted in a virtual format and the presentation will take place on Thursday, June 10, 2021, at 4:40 p.m. Eastern Time.

A live webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI^® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel^® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid^®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company’s website at www.vcel.com.

Epicel^® and MACI^® are registered trademarks of Vericel Corporation. NexoBrid^® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2021 Vericel Corporation. All rights reserved.

Investor Contacts:
Eric Burns
ir@vcel.com
+1 734-418-4411

FAQ

What is the date and time of Vericel's presentation at the Goldman Sachs Healthcare Conference?

Vericel's presentation is scheduled for June 10, 2021, at 4:40 p.m. Eastern Time.

How can I watch the Vericel presentation at the Goldman Sachs conference?

The presentation will be available via a live webcast on the Investor Relations section of Vericel's website.

What products does Vericel Corporation market?

Vericel markets MACI, an autologous cellularized scaffold, and Epicel, a permanent skin replacement for burn treatment.

Who is presenting on behalf of Vericel at the conference?

Nick Colangelo, the President and CEO of Vericel, will present at the conference.

What is the focus of Vericel Corporation's therapies?

Vericel focuses on advanced therapies for sports medicine and severe burn care.